Almirall, S.a.
Clinical trials sponsored by Almirall, S.a., explained in plain language.
A pharmaceutical company focused on dermatology and medical aesthetics.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New drug could help regrow hair in severe alopecia
Disease control Recruiting nowThis study tests a drug called LAD603 in 136 adults with severe to very severe alopecia areata, a condition causing significant hair loss. Participants will receive either the drug or a placebo to see if it helps regrow hair and is safe. The main goal is to measure changes in hai…
Phase: PHASE2 • Sponsor: Almirall, S.A. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for HS sufferers: LAD191 enters Mid-Stage trial
Disease control Recruiting nowThis study tests a new injectable drug called LAD191 in 200 adults with moderate-to-severe hidradenitis suppurativa (HS), a painful skin condition causing abscesses and scarring. Participants will receive either LAD191, a placebo, or an active comparator (adalimumab) to see if LA…
Phase: PHASE2 • Sponsor: Almirall, S.A. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug LAD106 enters first human safety tests
Knowledge-focused Recruiting nowThis early-stage study is testing a new drug called LAD106 in 93 healthy adults aged 18 to 45. The main goal is to see if it is safe and how the body processes it. Participants will receive either LAD106, a similar drug (lebrikizumab), or a placebo. This research is a first step …
Phase: PHASE1 • Sponsor: Almirall, S.A. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC